User:Anicm1/Amantadine/Bryantp1 Peer Review

Peer review
This is where you will complete your peer review exercise. Please use the following template to fill out your review.

General info

 * Anicm1
 * Amantadine

Lead evaluation
-Could mention some off-label uses in lead. – some of the highly rated articles have super big lead sections. See Alzheimer's. Want to mention all sections that will be discussed.

-Good summary of exactly what it is with first sentence.

Content evaluation
-I think you could move mechanism of action to be below "Chemical structure." Other articles are like that and I think it makes logical sense given the progression from chemistry to biochemistry/physiology, then clinical stuff.

-I think adverse effects, interactions, and contraindications should all be in sequence, maybe in that order?

-I think if you were looking to add more in there you could put in a section on pharmacology after chemical structure. - like pharmacokinetics/pharmacodynamics. See the Gabapentin article for an example.

-I thought your info on TBI was very compelling, especially since it sounds like it is an up-to-date and active area of research.

Tone and balance evaluation
-Good balanced tone throughout. Unbiased.

-I think the biggest low hanging fruit with this one is clearing up the language. Some of the sentences were grammatically incorrect or poorly worded. See below for some of the ones I picked out:

Under medical use section Parkinson’s disease - Amantadine may be used alone or combined with another anti-Parkinson or anticholinergic drug.

-Edit to “may be used alone or in combination with another anti-parkinson…”

* Actually about that section – maybe mention first how it is really used in combo with levodopa, then how it can be used alone but evidence as shown it doesn’t work.

EPS treatment section - has some pretty poor wording. Maybe something like “An extended release formulation is used in patients with Parkinson’s treated with levodopa to reduce side effects of dyskinesia.” Could just cite the WHO thing and don’t mention them.

MOA parkinsons section - Amantadine appears to be a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release, and blocks dopamine reuptake.

-Change to “increase dopamine release, and block dopamine reuptake.” Or something like that, depends on if the "appears to" applies to each of those MOA's. If not – then put the “appears to” at the end of the sentence.

MOA influenza section - By blocking the M2 channel, the virus is unable to replicate because of impaired replication, protein synthesis, and exocytosis.

-Second mention of replication is redundant.

Sources and references evaluation
Look good

Organization evaluation
-See above in "Content"

-I think you could just take out that section about "deja vu" at the end. Based on one case study seems tenuous and it really barely mentions Amantadine specifically.

-Looking at your edits I thought you did a good job getting some stuff stuff out that didn't need to be in there. You got out some poor citation and removed something that was plagiarized.

Overall great job!!!

Peter